Comparing Selective Laser Trabeculoplasty and Latanoprost Eye Drops for First Treatment of Early to Moderate Primary Open-Angle Glaucoma and Ocular Hypertension in Lagos

What this Trial Is About

Researchers are comparing the short-term effectiveness and safety of selective laser trabeculoplasty SLT against 0.005% latanoprost eye drops for lowering eye pressure in patients newly diagnosed with early to moderate primary open-angle glaucoma POAG or ocular hypertension OHT. The study aims to determine if SLT is as effective and safe as latanoprost eye drops when used as the first treatment option. It also evaluates how each treatment affects patients quality of life. Participants will be randomly assigned to one of two groups. One group will use 0.005% latanoprost eye drops every night for three months, while the other will receive a one-time SLT laser treatment. Intraocular pressure will be checked regularly over the three-month period, and any side effects will be recorded during follow-up visits. The study will take place at the Lagos State University Teaching Hospitals glaucoma clinic and will involve monitoring eye pressure changes over three months. Participants will have regular assessments to track treatment effects, side effects, and quality of life. The trial is designed to provide detailed information about how these treatments perform as initial therapy for glaucoma or ocular hypertension.

A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital